There is currently no text in this page. You can search for this page title in other pages, or search the related logs, but you do not have permission to create this page.
Category:CPC A61K31/4709
Pages in category "CPC A61K31/4709"
The following 44 pages are in this category, out of 44 total.
2
- 20250152574. Emopamil-binding Protein Inhibi (BIOGEN MA .)
- 20250152574. Emopamil-binding Protein Inhibi (BIOGEN MA INC.)
- 20250152575. Methods For Treating (X4 Pharmaceuticals, Inc.)
- 20250152575. Methods Treating (X4 Pharmaceuticals, .)
- 20250161292. Solid Forms ((s)-5 (FORMA Therapeutics, .)
- 20250161293. Crenolanib Trea (Arog Pharmaceuticals, .)
- 20250170120. Allosteric Sting Modulators Metho (THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM)
- 20250177373. Comp (THE CHILDREN'S MEDICAL CENTER)
- 20250177374. Bcl-xl Inhibitory Compounds Having (AbbVie .)
- 20250186424. Corneal Therapy (Unknown Organization)
- 20250186425. Pparg Inverse Agonists (Flare Therapeutics .)
- 20250195498. Inhibitor Cellular P (UNIWERSYTET WARSZAWSKI)
- 20250195499. Methods Pr (., . OF JEAMOON TECHNOLOGY)
- 20250228842. Uses Soma (Crinetics Pharmaceuticals, .)
- 20250228843. Compositions Cxcr4 (X4 Pharmaceuticals, .)
B
D
I
M
N
S
T
- The Regents of The University Of California Patent Application Trends in 2024
- THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Patent Application Trends in 2024
- The Regents of the University of California Patent Application Trends in 2025
- The Regents of The University Of California Patent Application Trends in 2025
- The Regents of the University of Colorado, a Body Corporate Patent Application Trends in 2024
- THE REGENTS OF THE UNIVERSITY OF MICHIGAN Patent Application Trends in 2024